Patent · US Active

Recombinant adenoviruses and use thereof

US10106781B2 · kind B2 · utility

4Cited by
2References
44Claims
0Family size

Assignees

Inventors

Key dates

Filing dateNov 15, 2013
Grant dateOct 23, 2018
Priority date
Expiry dateJun 18, 2034

Classification

  • Technology area (CPC Y)Emerging Cross-Sectional Technologies
  • CPC primaryY02A50/30
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention relates to recombinant adenoviruses and vectors thereof. In particular, the adenoviruses are novel simian adenoviruses having a low seroprevalence and high immunogenicity relative to other adenoviruses and vectors thereof. The invention also provides methods for production of the adenoviruses and for the treatment of diseases by administering the adenoviral vector(s) to a subject (e.g., a human).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.